ArticleFrontiers in medicine2026

Case Report: Differential response to IL-13 inhibition: lebrikizumab following primary tralokinumab failure in atopic dermatitis.

Shukry Abdi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.